NCT00415506

Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation

A PhaseI/II Prospective, Randomized, Dose-Ranging Pilot Study of Rituximab in the Treatment of Refractory Scleritis and Non-Infectious Orbital Inflammation

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Oregon Health and Science University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and tolerability of Rituximab in refractory scleritis and non-infectious orbital inflammation.

Conditions

• Scleritis
• Orbital Disease

Interventions

Type	Name	Description
DRUG	Rituximab	Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.

Timeline

• Start date: 2007-01-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2006-12-25
• Last updated: 2013-08-16
• Results posted: 2013-08-08

Locations

1 site across 1 country: United States